
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc. has received a positive outlook as its target price has increased from $44 to $46, reflecting higher net cash and a reduced share count. The company is witnessing progress in its clinical trials, particularly regarding its product DNTH103 and its differentiation from existing therapies like claseprubart. With an experienced management team and a focus on next-generation complement therapeutics, Dianthus Therapeutics is positioned well within the biotechnology sector, particularly for treating severe autoimmune and inflammatory diseases.
Bears say
Dianthus Therapeutics Inc. faces potential financial challenges due to their inability to secure adequate funding, which could hinder progress in advancing their drug pipeline. Furthermore, the elimination of an assumed offering in fiscal year 2028 and the subsequent reduction in shares for fiscal year 2025 suggest a reevaluation of the company's capital strategy. These factors contribute to a cautious outlook regarding the company's financial stability and its ability to sustain development operations.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares